Printer Friendly

Fuzeon update.

In January, new precautions were added to the labeling for the injectable HIV fusion inhibitor Fuzeon. The new information focuses on side effects reported when the Biojector 2000 needle-free device is used to inject Fuzeon. In addition, the correct injection sites are spelled out.

Patients using the Biojector 2000 needle-free device to inject Fuzeon may experience shooting nerve pain and tingling that can last for up to 6 months. This is caused by injecting the drug close to large nerves or near joints. In addition, bruising and collections of blood under the skin have been reported. Patients taking blood thinners, or patients with hemophilia or any other bleeding disorder, may be at higher risk of bruising or bleeding after using the Biojector.

The preferred body sites for injecting Fuzeon (regardless of the injection method) are the upper arm, abdomen, and upper thigh. Do not inject Fuzeon in the same area as you did the time before or where there is a current injection site reaction from an earlier dose. Fuzeon should not be injected near the elbow, knee, groin, or the lower or inner buttocks. In addition, Fuzeon should not be injected directly over a blood vessel; into moles, scar tissue, or bruises; or near the navel (belly button), surgical scars, tattoos, or burn sites.
COPYRIGHT 2007 The Center for AIDS: Hope & Remembrance Project
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:HIV Treatment: ALERTS!
Article Type:Brief article
Geographic Code:1USA
Date:Jun 1, 2007
Previous Article:Green tea: fact or fiction.
Next Article:Sustiva drug interactions.

Related Articles
T-20 (FUZEON) gets priority review.
T-20: most expensive AIDS drug ever at $25,000 per year?
The Food and Drug Administration (FDA) has approved a drug called Fuzeon for use in combination with other anti-HIV drugs to treat advanced HIV...
The outlook for HIV meds: a whole new class of anti-HIV drugs is on the horizon, but some patients are running out of time.
Entry inhibitors: hope on the horizon?
The price of Fuzeon resistance.
Tipranavir (Aptivus): approval cautiously recommended.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |